Cargando…
Modulating vascular intimal hyperplasia using HSV-1 mutant requires activated MEK
Outcomes of cardiovascular procedures, such as angioplasty and stent or bypass grafting are limited by failure, predominantly caused by pathological smooth muscle cell (SMC) proliferation, known as intimal hyperplasia. Local delivery of a genetically engineered herpes simplex virus (HSV) is known to...
Autores principales: | Skelly, C L, He, Q, Spiguel, L, McCormick, S, Weichselbaum, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567261/ https://www.ncbi.nlm.nih.gov/pubmed/22418062 http://dx.doi.org/10.1038/gt.2012.26 |
Ejemplares similares
-
Evidence for the Use of Multiple Mechanisms by Herpes Simplex Virus-1 R7020 to Inhibit Intimal Hyperplasia
por: McCormick, Susan, et al.
Publicado: (2015) -
Vascular smooth muscle cells in intimal hyperplasia, an update
por: Déglise, Sébastien, et al.
Publicado: (2023) -
Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy
por: Estep, Anne L., et al.
Publicado: (2007) -
ETS-targeted therapy: can it substitute for MEK inhibitors?
por: Tetsu, Osamu, et al.
Publicado: (2017) -
Axillary web syndrome with vascular thrombosis and arterial intimal hyperplasia
por: Mizuno, Hayato, et al.
Publicado: (2023)